Recent content by Drew_1984

Yes, actually brought this up with my own primary doctor too, saw rapid weight drop on a similar medication as well but couldn't stand the side effects.

The injection site change from abdomen to thigh is worth trying when side effects are severe at the current site - absorption rates differ between sites, and some people have dramatically different responses depending on where they inject. The thigh tends to produce slightly slower absorption...

The miserable first couple months where nausea hit after every shot, and then that clearing where you could eat normally, is exactly the mechanism settling into steady state rather than the sharp hit of each dose. The OP's day of normal eating after a dose that usually suppresses is the same...

The Hospira BAC water preference in the community comes from the established pharmaceutical grade documentation rather than anything wrong with supplier-included BAC. The clouding question is actually more about temperature history and proper reconstitution technique than the BAC source. Both...

Occasional suppression but food noise intact at 2 months is the non-responder profile at the current dose. The dose-response curve on semaglutide specifically tends to have a threshold effect where meaningful suppression doesn't engage until a certain level - 0.5 and 1mg are where most people...

Minimizing time above refrigerator temperature for reconstituted peptides is good practice - the bacteriostatic effect has limits, and reducing total warm time is a sensible default. Bacterial growth is the practical concern to manage rather than compound degradation.

the 1 percent of body weight per week ceiling is the practical version of the clinical guidance for sustainable loss - above that threshold the deficit required is either not sustainable through diet alone or is aggressive enough to draw meaningfully from lean tissue. the first few weeks on...

the lipid panel as a conversation tool is smart - it takes the 'what are you on and why' question and grounds it in something objective and medical. most skeptics who see concrete before-and-after blood work go quiet pretty fast. leading with the outcome rather than the method is the right...

Starting the diet cycle in 2nd grade is one of the more harrowing things people share on here and it puts the two years on GLP-1 in a completely different frame. The interventions available in childhood versus now are not even comparable. Two years is a long time to stick with anything - what...

20mg is at the ceiling of what's been studied for tirzepatide in trials, so going beyond that puts you firmly in experimental territory without established dosing guidance. The synergy with metformin for insulin sensitization is actually well-documented - that combination tends to have additive...

5'7, started February, never above 1mg, averaging 1 pound a week across the run, high weight 245 but started at 200, now at 144 in maintenance - that is a remarkably clean low-dose trajectory. The OP's 7 months at similar starting demographics is a useful benchmark for someone who hasn't hit...

The maintenance dose decision after hitting goal is the one most forums gloss over after the milestone post. The evidence on regain after full discontinuation is strong enough that the 'better safe than sorry' logic for a maintenance dose is well-founded. 24 months to get there with behavioral...

The week 3 weak feeling and then full blast satiety returning at weeks 4-5 is the adaptation curve that makes early dose changes premature. The OP's exhaustion after bumping to 7.5mg is the dose adjustment hitting before the body adjusts. Giving the new dose a few more weeks before concluding...

The tolerance reset not happening after a 6-week break and needing 12.5mg to recapture the effect is consistent with what's documented. Adding cagri on top of tirz targets the amylin receptor independently rather than pushing the GLP-1 pathway harder. Week 3 is still early for cagri's satiety...

4 months of sema in a caloric deficit with zero movement and then switching to tirzepatide is a common non-responder to responder transition. The GIP receptor angle in tirz covers something sema does not, and people who did not respond to sema often do respond to tirz. The third month is usually...